PLX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PLX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Protalix BioTherapeutics's Revenue for the three months ended in Dec. 2023 was $10.49 Mil. Protalix BioTherapeutics's Total Assets for the quarter that ended in Dec. 2023 was $86.00 Mil. Therefore, Protalix BioTherapeutics's Asset Turnover for the quarter that ended in Dec. 2023 was 0.12.
Asset Turnover is linked to ROE % through Du Pont Formula. Protalix BioTherapeutics's annualized ROE % for the quarter that ended in Dec. 2023 was -67.33%. It is also linked to ROA % through Du Pont Formula. Protalix BioTherapeutics's annualized ROA % for the quarter that ended in Dec. 2023 was -28.11%.
The historical data trend for Protalix BioTherapeutics's Asset Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Protalix BioTherapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Asset Turnover | Get a 7-Day Free Trial | 1.03 | 1.11 | 0.54 | 0.74 | 0.93 |
Protalix BioTherapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Asset Turnover | Get a 7-Day Free Trial | 0.15 | 0.16 | 0.45 | 0.12 | 0.12 |
For the Biotechnology subindustry, Protalix BioTherapeutics's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Protalix BioTherapeutics's Asset Turnover distribution charts can be found below:
* The bar in red indicates where Protalix BioTherapeutics's Asset Turnover falls into.
Asset Turnover measures how quickly a company turns over its asset through sales.
Protalix BioTherapeutics's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as
Asset Turnover | ||||||
= | Revenue | / | Average Total Assets | |||
= | Revenue (A: Dec. 2023 ) | / | ( (Total Assets (A: Dec. 2022 ) | + | Total Assets (A: Dec. 2023 )) | / count ) |
= | 65.494 | / | ( (55.787 | + | 84.434) | / 2 ) |
= | 65.494 | / | 70.1105 | |||
= | 0.93 |
Protalix BioTherapeutics's Asset Turnover for the quarter that ended in Dec. 2023 is calculated as
Asset Turnover | ||||||
= | Revenue | / | Average Total Assets | |||
= | Revenue (Q: Dec. 2023 ) | / | ( (Total Assets (Q: Sep. 2023 ) | + | Total Assets (Q: Dec. 2023 )) | / count ) |
= | 10.486 | / | ( (87.569 | + | 84.434) | / 2 ) |
= | 10.486 | / | 86.0015 | |||
= | 0.12 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.
Protalix BioTherapeutics (AMEX:PLX) Asset Turnover Explanation
Asset Turnover is linked to ROE % through Du Pont Formula.
Protalix BioTherapeutics's annulized ROE % for the quarter that ended in Dec. 2023 is
ROE %** | (Q: Dec. 2023 ) | ||||
= | Net Income | / | Total Stockholders Equity | ||
= | -24.176 | / | 35.908 | ||
= | (Net Income / Revenue) | * | (Revenue / Total Assets) | * | (Total Assets / Total Stockholders Equity) |
= | (-24.176 / 41.944) | * | (41.944 / 86.0015) | * | (86.0015/ 35.908) |
= | Net Margin % | * | Asset Turnover | * | Equity Multiplier |
= | -57.64 % | * | 0.4877 | * | 2.3951 |
= | ROA % | * | Equity Multiplier | ||
= | -28.11 % | * | 2.3951 | ||
= | -67.33 % |
Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.
It is also linked to ROA % through Du Pont Formula:
Protalix BioTherapeutics's annulized ROA % for the quarter that ended in Dec. 2023 is
ROA % | (Q: Dec. 2023 ) | ||
= | Net Income | / | Total Assets |
= | -24.176 | / | 86.0015 |
= | (Net Income / Revenue) | * | (Revenue / Total Assets) |
= | (-24.176 / 41.944) | * | (41.944 / 86.0015) |
= | Net Margin % | * | Asset Turnover |
= | -57.64 % | * | 0.4877 |
= | -28.11 % |
Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.
Thank you for viewing the detailed overview of Protalix BioTherapeutics's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.
Dror Bashan | director, officer: President and CEO | 2 SNUNIT ST, SCIENCE PARK, POB 455, CARMIEL L3 L3 20100 |
Eliot Forster | director | C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT |
Aharon Schwartz | director | C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT STREET, SCIENCE PARK, #455, CARMIEL L3 20100 |
Zvi Shmuel Ben | director | 2 SNUNIT STREET, SCIENCE PARK, #455, CARMIEL L3 2161401 |
Dexcel Pharma Technologies Ltd. | 10 percent owner | 1 DEXCEL STREET, OR AKIVA L3 3060000 |
Dan Oren | 10 percent owner | 1 DEXCEL STREET, OR AKIVA L3 30600000 |
Eyal Rubin | officer: Sr. VP and CFO | C/O BRAINSTORM CELL THERAPEUTICS INC.,, 3 UNIVERSITY PLAZA DRIVE, STE 320, HACKENSACK NJ 07601 |
Yaron Naos | officer: Sr. VP, Operations | 2 SNUNIT STREET, SCIENCE PARK, POB 455, CARMIEL L3 20100 |
Yael Hayon | officer: Vice President, R&D | 2 SNUNIT STREET, SCIENCE PARK, POB 455, CARMIEL L3 2161401 |
Zeev Bronfeld | director | 6 URI STREET, TEL AVIV L3 64954 |
Amos Bar-shalev | director | C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT ST, SCIENCE PARK, POB 455, CARMIEL L3 20100 |
David Granot | director | 6225 NEIL ROAD, RENO NV 89511 |
Pol F Boudes | director | C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560 |
Gwen A Melincoff | director | C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Moshe Manor | officer: President & CEO | C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT STREET, SCIENCE PARK, #455, CARMIEL L3 20100 |
From GuruFocus
By GuruFocus Research • 11-06-2023
By PRNewswire PRNewswire • 02-27-2023
By PRNewswire PRNewswire • 04-27-2023
By PRNewswire PRNewswire • 12-04-2022
By PRNewswire PRNewswire • 05-04-2023
By PRNewswire PRNewswire • 12-21-2022
By PRNewswire PRNewswire • 03-21-2023
By PRNewswire PRNewswire • 11-14-2022
By PRNewswire PRNewswire • 02-24-2023
By PRNewswire PRNewswire • 11-07-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.